Adherence to antihypertensive medications: A review and update

High Blood Pressure and Cardiovascular Prevention

Volumn 16, Issue 3, 2009, Pages 101-110

  Costa, Francesco Vittorio ^a   D'Ausilio, Anna ^b   Bianchi, Cosetta ^c   Negrini, Cristina ^b   Lopatriello, Stefania ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Pbe Consulting   (Italy)

^c Bayer Schering Pharma Viale Certosa ^*  (Italy)

^d PBE Consulting   (Italy)

Author keywords

Adherence to treatment; Antihypertensive drugs; Compliance to treatment; Cost of non compliance; Treatment discontinuation

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; PERINDOPRIL; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; FOLLOW UP; HUMAN; HYPERTENSION; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 70349286671     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.2165/11530330-000000000-00000     Document Type: Review

References (67)

1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 Aug 4; 353 (5): 487-497
2. Dunbar-Jacob J, Erlen JA, Schlenk EA, et al. Adherence in chronic disease. Annu Rev Nurs Res 2000; 18: 48-90.
3. Flack JM, Casciano R, Casciano J, et al. Cardiovascular disease costs associated with uncontrolled hypertension.Manag Care Interface 2002; 15: 28-36
4. Hansson L. 'Why don't you do as I tell you?': compliance and antihypertensive regimens. Int J Clin Pract 2002 Apr; 56 (3): 191-196
5. Hansson L, Lloyd A, Anderson P, et al. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press 2002; 11 (1): 35-45
6. Kotseva K, Wood D, De BG, et al.EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009 Apr; 16 (2): 121-137
7. Elliott WJ. Compliance - and improving it - in hypertension. Manag Care 2003 Aug; 12 (8 Suppl.): 56-61
8. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005 Jan 15; 365 (9455): 217-223
9. Lopatriello S, Berto P, Cramer J, et al. Different aspects of adherence to antihypertensive treatments. Expert Rev Pharmacoeconomics Outcomes Res 2004; 4 (3): 317-333
10. Gohar F, Greenfield SM, Beevers DG, et al. Self-care and adherence to medication: a survey in the hypertension outpatient clinic. BMC Complement Altern Med 2008; 8: 4, doi:10.1186/1472-6882-8-4
11. Hyre AD, Krousel-Wood MA, Muntner P, et al. Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting. J Clin Hypertens (Greenwich) 2007 Mar; 9 (3): 179-186
12. Lehane E, McCarthy G. An examination of the intentional and unintentional aspects of medication non-adherence in patients diagnosed with hypertension. J Clin Nurs 2007 Apr; 16 (4): 698-706
13. Marquez-Contreras E, Martell-Claros N, Gil-Guillen V, et al. Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: theEAPACUM-HTAstudy. J Hypertens 2006 Jan; 24 (1): 169-175
14. Schroeder K, Fahey T, Hay AD, et al. Adherence to antihypertensive medication assessed by self-report was associated with electronic monitoring compliance. J Clin Epidemiol 2006 Jun; 59 (6): 650-651
15. Wetzels G, Nelemans P, van WB, et al. Determinants of poor adherence in hypertensive patients: development and validation of the 'Maastricht Utrecht Adherence in Hypertension (MUAH)-questionnaire'. Patient Educ Couns 2006 Dec; 64 (1-3): 151-158
16. Zeller A, Schroeder K, Peters TJ. An adherence self-report questionnaire facilitated the differentiation between nonadherence and nonresponse to antihypertensive treatment. J Clin Epidemiol 2008 Mar; 61 (3): 282-288
17. Bautista LE. Predictors of persistence with antihypertensive therapy: results from the NHANES. Am J Hypertens 2008 Feb; 21 (2): 183-188
18. Bramley TJ,Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006 Apr; 12 (3): 239-245
19. Fodor GJ, Kotrec M, Bacskai K, et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central- European study. J Hypertens 2005 Jun; 23 (6): 1261-1266
20. Fung V, Huang J, Brand R, et al. Hypertension treatment in a Medicare population: adherence and systolic blood pressure control. Clin Ther 2007 May; 29 (5): 972-984
21. Grant RW, Singer DE, Meigs JB. Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data. Clin Ther 2005 Jun; 27 (6): 773-781
22. Lowry KP, Dudley TK, Oddone EZ, et al. Intentional and unintentional nonadherence to antihypertensive medication. Ann Pharmacother 2005 Jul; 39 (7-8): 1198-1203
23. Ross S, Walker A, MacLeod MJ. Patient compliance in hypertension: role of illness perceptions and treatment beliefs. J Hum Hypertens 2004 Sep; 18 (9): 607-613
24. Van Wijk BL, Klungel OH, Heerdink ER, et al. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother 2006 Jan; 40 (1): 15-20
25. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008 May 17; 336 (7653): 1114-1117
26. Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertensionmedications. Am J Manag Care 2005 Jan; 11 spec. no: SP27-34
27. Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005 Jun; 12 (3): 243-249
28. Borghi C, Veronesi M, Dormi A, et al. Persistence of treatment and blood pressure control in elderly hypertensive patients treated with different classes of antihypertensive drugs. Am J Geriatr Cardiol 2007 Sep; 16 (5): 280-286
29. Bourgault C, Senecal M, Brisson M, et al. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population- based study. J Hum Hypertens 2005 Aug; 19 (8): 607-613
30. Burke TA, Sturkenboom MC, Lu SE, et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006 Jun; 24 (6): 1193-1200
31. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008 Apr; 26 (4): 819-824
32. Degli EE, Sturani A, Di MM, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002 Jun; 16 (6): 439-444
33. Erkens JA, Panneman MM, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005 Nov; 14 (11): 795-803
34. Hasford J, Schroder-Bernhardi D, Rottenkolber M, et al. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol 2007 Nov; 63 (11): 1055-1061
35. Lachaine J, Petrella RJ,Merikle E, et al. Choices, persistence and adherence to antihypertensive agents: evidence fromRAMQdata. Can J Cardiol 2008 Apr; 24 (4): 269-273
36. Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005 Nov; 23 (11): 2093-2100
37. Morgan SG, Yan L. Persistence with hypertension treatment among community- dwelling BC seniors. Can J Clin Pharmacol 2004; 11 (2): e267-73
38. Patel BV, Remigio-Baker RA, MehtaD, et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens (Greenwich) 2007 Sep; 9 (9): 692-700
39. Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother 2005 Sep; 39 (9): 1401-1408
40. Poluzzi E, Strahinja P, Vargiu A, et al. Initial treatment of hypertension and adherence to therapy in general practice in Italy. Eur J Clin Pharmacol 2005 Sep; 61 (8): 603-609
41. Prandin MG, Cicero AF, Veronesi M, et al. Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: a prospective evaluation. Clin Exp Hypertens 2007 Nov; 29 (8): 553-562
42. Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med 2007 Jan; 120 (1): 26-32
43. Stroupe KT, Teal EY, Tu W, et al. Association of refill adherence and health care use among adults with hypertension in an urban health care system. Pharmacotherapy 2006 Jun; 26 (6): 779-789
44. Van Wijk BL, Klungel OH, Heerdink ER, et al. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens 2004 Sep; 22 (9): 1831-1837
45. Van Wijk BL, Klungel OH, Heerdink ER, et al. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005 Nov; 23 (11): 2101-2107
46. Van Wijk BL, Klungel OH, Heerdink ER, et al. Initial non-compliance with antihypertensive monotherapy is followed by complete discontinuation of antihypertensive therapy. Pharmacoepidemiol Drug Saf 2006 Aug; 15 (8): 587-593
47. Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag 2007; 3 (6): 999-1005
48. Vinker S, Alkalay A, Hoffman RD, et al. Long-term adherence to antihypertensive therapy: a survey in four primary care clinics. Expert Opin Pharmacother 2008 Jun; 9 (8): 1271-1277
49. Poluzzi E, Strahinja P, Vaccheri A, et al. Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. Br J Clin Pharmacol 2007 Mar; 63 (3): 346-355
50. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008; 8 (1): 45-50
51. Elliott WJ, Plauschinat CA, Skrepnek GH, et al. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensiv drug monotherapies. J Am Board Fam Med 2007 Jan; 20 (1): 72-80
52. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007 Jun; 64 (12): 1279-1283
53. Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004-2006. Med J Aust 2008 Feb 18; 188 (4): 224-227
54. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixeddose amlodipine besylate/benazepril HCl versus comparable componentbased therapy. Congest Heart Fail 2003 Nov; 9 (6): 324-332
55. Koylan N, Acarturk E, Canberk A, et al. Effect of irbesartan monotherapy compared with ACE inhibitors and calcium-channel blockers on patient compliance in essential hypertension patients: a multicenter, open-labeled, three-armed study. Blood Press Suppl 2005 Jul; 1: 23-31
56. Mengden T, Vetter H, Tousset E, et al. Management of patients with uncontrolled arterial hypertension: the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCTZ. BMC Cardiovasc Disord 2006; 6: 36, doi:10.1186/1471-2261-6-36
57. Burnier M, Santschi V, Favrat B, et al. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens Suppl 2003 May; 21 (2): S37-42
58. Cherry SB, Benner JS, Hussein MA, et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health 2008 Sep 9; 12 (4): 489-497
59. Kettani FZ, Dragomir A, Cote R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009 Jan; 40 (1): 213-220
60. Evers SM, Struijs JN, Ament AJ, et al. International comparison of stroke cost studies. Stroke 2004 May; 35 (5): 1209-1215
61. Leal J, Luengo-Fernandez R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006 Jul; 27 (13): 1610-1619
62. Messerli FH, Bangalore S, Ram VS. Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med 2008 Jul 24; 359 (4): 426-427
63. Gosse P. A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours. Vasc Health Risk Manag 2006; 2 (3): 195-201
64. Lacourciere Y, Krzesinski JM, White WB, et al. Sustained antihypertensive activity of telmisartan comparedwith valsartan. Blood Press Monit 2004 Aug; 9 (4): 203-210
65. Doshi JA, Zuckerman IH, Picot SJ, et al. Antihypertensive use and adherence and blood pressure stress response among black caregivers and non-caregivers. Appl Nurs Res 2003 Nov; 16 (4): 266-277
66. Marquez CE, Vegazo GO, Claros NM, et al. Efficacy of telephone and mail intervention in patient compliance with antihypertensive drugs in hypertension. ETECUM-HTA study. Blood Press 2005; 14 (3): 151-158
67. Schroeder K, Fahey T, Hollinghurst S, et al. Nurse-led adherence support in hypertension: a randomized controlled trial. FamPract 2005 Apr; 22 (2): 144-151